LITI-CAPITAL
Liti Capital is announcing that a Steering Committee has been formed to support traders in their pursuit of recovery against Binance for losses caused when the world’s biggest cryptocurrency exchange failed.
On May 19, 2021, when markets were turning red, Binance’s platform failed. As a result, the trading accounts (including Futures, Margin, and Leveraged Token products) of at least 700 and potentially thousands of individuals were effectively untradeable for hours, causing traders to suffer losses that may exceed one hundred million dollars.
Binance account holders who traded on the platform and suffered losses then and possibly at other times as a result of the platform’s failure can seek compensation from Binance. A number of traders have tried to resolve matters with Binance short of pursuing legal claims, but so far have been unsuccessful.
If traders seeking compensation are unable to resolve their disputes with Binance satisfactorily, they may submit disputes to international arbitration, a costly step for an individual.
Several traders that suffered losses due to the failure of Binance’s platform intend to seek compensation from Binance, including through arbitration, if necessary. Initially advised by Ms. Aija Lejniece, a Paris-based arbitration attorney, these traders have established a Steering Committee to provide guidance and information about the claims process against Binance.
The Steering Committee has arranged for Liti Capital SA, a Swiss-based blockchain private equity fund specializing in raising capital for legal cases, to provide funding in order to permit individual traders who suffered damages as a result of the failure of Binance’s trading platform to pursue the claims process. Litigation finance is frequently used by claimants to pay for the costs of preparing and pursuing legal claims in exchange for a minority percentage of compensation received. Liti Capital, the first and largest private equity fund on the blockchain, uses LITI token to raise capital to invest in cases they believe have merit.
Liti Capital’s funding will enable affected individuals to pursue claims, including, if necessary, in arbitration, for compensation against Binance. The international law firm of White & Case LLP has been engaged to represent affected individuals in the claims process.
The Steering Committee counts Ms. Lejniece, Mr. David Kay of Liti Capital and three of the affected traders among its members. Individuals who believe they were damaged by the failure of Binance’s platform and wish to seek compensation may contact the Steering Committee for more information by email at sc@binanceclaim.com or may refer to its website at http://www.binanceclaim.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210819005665/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release
New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release
First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom